Product Catalog
Manufacturer: BioTissue
Ocular Surface Repair + Protection, Ophthalmology
CAM360 AmnioGraft 12mm
Item #: AG-360-12Manufacturer: BioTissue
Developed to optimize comfort.
CAM360 AmnioGraft™ (CAM360 AG) is the first and only hydrated, cryopreserved amniotic membrane developed to optimize comfort that exerts anti-inflammatory, anti-scarring, anti-angiogenic properties for ocular use.1
Applications:
- Dry Eye Disease
- Superficial Punctate Keratitis (SPK)
- Ocular surface optimization
- Glaucoma-medication induced dry eye
- Neurotrophic keratitis stage 1
- Mild-to-moderate dry eye disease
- Reduce signs and symptoms of Dry Eye Disease (DED)
- Support epithelial adhesion and differentiation
- Promote corneal nerve regeneration
- Ringless: CAM360 AG is a comfortable, ringless, Cryopreserved Amniotic Membrane (CAM) option, ideal for superficial conditions.
- Shelf-Stable: The SteriTek preservation process yields a shelf-stable product, protecting the bioactive components of the tissue without heat dehydration.2
- Adhesive Property: Our proprietary processing method preserves the tissue’s unique, adhesive property allowing CAM360 AG to stick and stay under a Collagen Shield or Bandage Contact Lens (BCLs).4
- Location and Temperature:-20°C → 25°C ( -4°F → 77°F)
- Shelf Life: Use within the expiration date printed on product packaging (18 months from date of manufacture)
-
1. FDA RFD
- 2. Data on File
- 4. Cooke, M., . (2014). Comparison of cryopreserved amniotic membrane and umbilical cord tissue with dehydrated amniotic membrane/chorion tissue. Journal of Wound Care, 23(10), 465-476.
- 5. John, T., et al. (2017). Corneal nerve regeneration after self-retained cryopreserved amniotic membrane in dry eye disease. Journal of Ophthalmology, 2017.
- 6. McDonald, M. B., et al. (2018). Treatment outcomes in the dry eye amniotic membrane (DREAM) study. Clinical Ophthalmology (Auckland, NZ), 12, 677.
- 7. Cheng, A. M., et al. (2016). Accelerated restoration of ocular surface health in dry eye disease by self-retained cryopreserved amniotic membrane. The Ocular Surface, 14(1), 56-63.
- 8. Vendal, Z. (2022). Management of glaucoma medication induced dry eye disease with self-retained cryopreserved amniotic membrane. Journal of Dry Eye Disease, 5(1), e28-e34.
- Open Market